Cetrorelix vs LH

Competitive GnRH receptor antagonist; immediately blocks pituitary GnRH receptors; rapidly suppresses LH/FSH without initial flare effect; used for controlled hormonal suppression

Cetrorelix is a synthetic GnRH antagonist peptide used in assisted reproductive technology (ART) to prevent premature luteinizing hormone (LH) surges during controlled ovarian stimulation protocols. By competitively blocking GnRH receptors in the pituitary gland, cetrorelix rapidly suppresses LH release without the initial hormonal flare seen with GnRH agonists, allowing more precise timing of oocyte retrieval. Clinical studies including randomized controlled trials have established cetrorelix as an effective option for LH surge prevention in IVF and ICSI cycles, with well-characterized safety and efficacy data across multiple formulations. Cetrorelix is an FDA-approved prescription medication (Cetrotide) indicated for use under specialist supervision in fertility treatment settings. Cetrorelix dosing protocols and IVF context In IVF, cetrorelix is used under two standard protocols. The multiple-dose protocol administers 0.25mg subcutaneously once daily starting from stimulation day 5 or 6, continuing until the day of oocyte trigger — this prevents LH surge during the follicular growth phase. The single-dose protocol administers 3mg once when the leading follicle reaches approximately 14mm, providing LH suppression for approximately 96 hours; a supplemental 0.25mg dose is added if trigger has not occurred by day 4. Both protocols have established efficacy data and are used depending on clinic preference and patient response characteristics. Cetrorelix vs ganirelix: Cetrorelix (Cetrotide) and ganirelix (Antagon, Orgalutran) are both GnRH receptor antagonists used in the same IVF indication. Both act as competitive antagonists at the pituitary GnRH receptor, producing rapid suppression without the initial LH flare seen with agonists. They are pharmacologically equivalent in mechanism; differences relate to proprietary formulation, dosing schedule in specific protocols, and market availability in different regions. Neither requires the weeks-long downregulation period that GnRH agonist protocols (triptorelin, leuprolide) involve — antagonist protocols can begin mid-stimulation, reducing the total cycle length. Cetrorelix and ganirelix are both prescription-only fertility medications requiring specialist reproductive endocrinology supervision.

Binds LH receptors on testicular Leydig cells, stimulating the cholesterol → testosterone biosynthetic pathway. In women, the LH surge triggers ovulation and supports luteal phase progesterone production.

LH (luteinizing hormone) is an endogenous heterodimeric glycoprotein hormone produced by pituitary gonadotrophs, sharing the common alpha subunit with FSH, TSH, and hCG, with a unique LH-beta subunit structurally homologous to hCG-beta; LH drives sex steroid synthesis through pulsatile release regulated by hypothalamic GnRH, and mediates the midcycle LH surge that triggers ovulation in women and sustains Leydig cell testosterone production in men. LH activates its receptor (LHR/LHCGR) on ovarian theca cells to stimulate androgen synthesis (which granulosa cells aromatize to estrogen under FSH regulation) and triggers follicular rupture and corpus luteum formation during the ovulatory surge; in men, tonic LH stimulates Leydig cell testosterone biosynthesis through cAMP/StAR pathway activation. A double-blind randomized controlled trial of supplemental recombinant LH (lutropin alfa) during controlled ovarian stimulation for ART demonstrated comparable clinical outcomes to FSH-only protocols in patients with baseline LH deficiency, providing evidence that lutropin alfa can serve as an effective LH substitute in gonadotropin-deficient women undergoing fertility treatment. Lutropin alfa (Luveris; Pergoveris in co-formulation with FSH) is approved in the European Union and several other jurisdictions for stimulation of follicular development in women with profound LH deficiency, but is not broadly approved in the United States; endogenous LH is not used as a therapeutic agent, and hCG — structurally similar to LH with a longer plasma half-life — is typically used as an LH surrogate for ovulation triggering and luteal phase support in US clinical practice.